NorthWest Biotherapeutics Inc (NWBO)

[jimmy667]

Yes this is correct. Thank you ATLInsider. NWBO used an external control arm (ECA).  The discussions of ECAs consisting of Real World Evidence. In other words the Data collected from the treatment of patients in a treatment setting rather than a clinical trial might be considered when other Control groups are not available or to supplement those control groups. This may be important in future NWBO trials to expand the label of DC-Vax-L.As I read you post you are saying the External Control Arm in the NWBO trial was a carefully "distilled" ECA consisting NOT of RWE but of a careful amalgamation of control arms from other published clinical trials.One of the main features and conclusions of the JAMA Article was the agreement with and validation of the ECA consisting of a amalamation of other contemporary clinical trial control arms done by subject matter expert researchers contracted by NWBO. Everything about this ECA analysis done on behalf of the NWBO trial was cutting edge top notch science. The JAMA Article is essence declared the ECA methods used by the NWBO outside experts as the new current State of the Art. 
Now MHRA is codifying this use of ECAs as used by NWBO as one of the methods of ECAs recognized as legitimate in regulatory practice. This same proposed also recognizes RWE as legitimate. But RWE was not the NWBO trial  control arm. RWE would be the clinical experience of the results of the specials "compassionate use" patients for which patient level data is available. Thank you ATLINSIDER for clearing up some of the fuzzy thinking regarding the NWBO clinical trial ECA. Actually JAMA has already declared the methods used as the new State ofthe Art and the Groundbreaking NWBo Trial as an unmitigated success.
Success of NWBO is assured beyond even a sliver of doubt.
 The only doubts are from criticisms and disparagements from compromised and possibly criminal actors imposed upon the fuzzy thinking of weary retail investors. 
Focus people. JAMA verified the soundness of the science. MHRA is codifing the NWBO trial ECA trial protocol. When MHRA approves DC-Vax,-L the market for NWBO stock will 'flash over".